First patient dosed in Phase 1 clinical trial for preventive migraine treatment
The first individuals have been dosed in a Phase 1 clinical trial of UB-313, a vaccine targeting calcitonin gene-related peptide (CGRP), for the preventive treatment of migraine, according to a press release by Vaxxinity, Inc.
The trial will enroll 40 healthy volunteers and will evaluate safety, tolerability, and immunogenicity, measured by serum anti-CGRP antibody titers.
“Therapeutics targeting the CGRP pathway have been identified as an effective treatment option for chronic and episodic migraines. Following the success of monoclonal antibodies for the prevention of migraine and small molecule CGRP-receptor antagonists for migraine prevention and acute treatment, an immunotherapeutic vaccine could bring about a transformational third wave of options for patients,” said
Jan de Hoon, MD, Professor in Pharmacology and Clinical Pharmacology, KU Leuven in Belgium, and principal investigator.
Read the full press release here.
